ATE217195T1 - Verwendung von cilastatin, glutathione und n- acetyl-l-cysteine zur herstellung eines arzneimittels zur verbesserung der resorption von carbapenem oder penem antibiotika im magen-darm- trakt - Google Patents

Verwendung von cilastatin, glutathione und n- acetyl-l-cysteine zur herstellung eines arzneimittels zur verbesserung der resorption von carbapenem oder penem antibiotika im magen-darm- trakt

Info

Publication number
ATE217195T1
ATE217195T1 AT92101563T AT92101563T ATE217195T1 AT E217195 T1 ATE217195 T1 AT E217195T1 AT 92101563 T AT92101563 T AT 92101563T AT 92101563 T AT92101563 T AT 92101563T AT E217195 T1 ATE217195 T1 AT E217195T1
Authority
AT
Austria
Prior art keywords
cilastatin
glutathione
cysteine
acetyl
absorption
Prior art date
Application number
AT92101563T
Other languages
English (en)
Inventor
Osamu Sugita
Yasushi Kanai
Takumi Kojima
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP3147591A external-priority patent/JP3377219B2/ja
Priority claimed from JP03147891A external-priority patent/JP3161741B2/ja
Priority claimed from JP03147691A external-priority patent/JP3148263B2/ja
Priority claimed from JP3147791A external-priority patent/JP3178726B2/ja
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE217195T1 publication Critical patent/ATE217195T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92101563T 1991-02-01 1992-01-30 Verwendung von cilastatin, glutathione und n- acetyl-l-cysteine zur herstellung eines arzneimittels zur verbesserung der resorption von carbapenem oder penem antibiotika im magen-darm- trakt ATE217195T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP3147591A JP3377219B2 (ja) 1991-02-01 1991-02-01 経口抗菌組成物
JP03147891A JP3161741B2 (ja) 1991-02-01 1991-02-01 ペネム類の消化管吸収改善剤および改善方法
JP03147691A JP3148263B2 (ja) 1991-02-01 1991-02-01 抗菌性組成物
JP3147791A JP3178726B2 (ja) 1991-02-01 1991-02-01 抗菌剤組成物

Publications (1)

Publication Number Publication Date
ATE217195T1 true ATE217195T1 (de) 2002-05-15

Family

ID=27459440

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01118037T ATE297205T1 (de) 1991-02-01 1992-01-30 Orale antibakterielle zusammensetzung und verfahren zur verbesserung der resorption von penem oder carbapenem antibiotika im magen-darm- traktus
AT92101563T ATE217195T1 (de) 1991-02-01 1992-01-30 Verwendung von cilastatin, glutathione und n- acetyl-l-cysteine zur herstellung eines arzneimittels zur verbesserung der resorption von carbapenem oder penem antibiotika im magen-darm- trakt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01118037T ATE297205T1 (de) 1991-02-01 1992-01-30 Orale antibakterielle zusammensetzung und verfahren zur verbesserung der resorption von penem oder carbapenem antibiotika im magen-darm- traktus

Country Status (5)

Country Link
US (2) US5354748A (de)
EP (2) EP1161947B1 (de)
AT (2) ATE297205T1 (de)
DE (2) DE69233529T2 (de)
ES (2) ES2176179T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
JP2001507696A (ja) 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション グルタチオンの医薬製剤およびその投与方法
US6365635B1 (en) * 1998-01-13 2002-04-02 Suntory Limited Antibacterial composition for topical administration containing antibiotic
CN1198611C (zh) 1999-09-17 2005-04-27 第一三得利制药株式会社 药物抗菌剂组合物
US20040202714A1 (en) * 1999-10-12 2004-10-14 Daiichi Suntory Pharma Co., Ltd. Oral pharmaceutical composition
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
CA2868343A1 (en) * 2011-03-24 2012-09-27 Seachaid Pharmaceuticals, Inc. Vancomycin derivatives
CN103371977A (zh) * 2012-04-25 2013-10-30 秦引林 一种泰比培南酯颗粒及其制备方法
US9913801B2 (en) * 2013-02-15 2018-03-13 Your Energy Systems, LLC Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668504A (en) * 1970-11-18 1987-05-26 Merck & Co., Inc. Use of substituted propenoates to prevent nephrotoxicity of certain antibiotics
US4301074A (en) * 1977-11-17 1981-11-17 Merck & Co., Inc. 6-(1'-Hydroxyethyl)-2-substituted-pen-2-em-3-carboxylic acid
US4168314A (en) * 1977-11-17 1979-09-18 Merck & Co., Inc. 6-(1'-Hydroxyethyl)-2-aminoethylthio-pen-2-em-3-carboxylic acid
US4880793A (en) * 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
AR244550A1 (es) * 1978-07-24 1993-11-30 Merck & Co Inc Procedimiento para obtener una composicion de antibioticos del tipo de la tienamicina con inhibidores de la dipeptidasa
US4616038A (en) * 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
NZ190994A (en) * 1978-07-24 1981-10-19 Merck & Co Inc Z-2-acylamino-3-monosubstituted propenoates
US4272437A (en) * 1978-12-18 1981-06-09 Bristol-Myers Company Antibacterial agents, and 4-thio azetidinone intermediates
US4539208A (en) * 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4378314A (en) * 1979-09-21 1983-03-29 Bristol Myers Company Antibacterial agents and metal containing azetidinone intermediates therefore
GR70784B (de) * 1979-11-02 1983-03-23 Merck & Co Inc
US4386030A (en) * 1979-12-31 1983-05-31 Merck & Co., Inc. Process for preparing 6-(1'-hydroxyethyl)-2-substituted-pen-2-em-3-carboxylic acid
PT73640B (en) * 1980-09-17 1983-10-19 Merck & Co Inc Process for preparing chemical compounds selectively inhibit the metabolism of dipeptidase
US4406902A (en) * 1980-09-17 1983-09-27 Merck & Co., Inc. Dipeptidase inhibitors
NZ201471A (en) * 1981-08-10 1985-09-13 Merck & Co Inc Antibacterial compositions containing penems and dipeptidase inhibitors
JPH075463B2 (ja) * 1985-03-09 1995-01-25 サントリー株式会社 抗菌剤
US4739113A (en) * 1986-05-30 1988-04-19 Merck & Co., Inc. Bis(cyclopropanecarboxamido)alkadienedioic acids as renal dipeptidase inhibitors
US5061730A (en) * 1987-01-26 1991-10-29 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid derivatives
US4866171A (en) * 1987-04-11 1989-09-12 Lederle (Japan), Ltd. (1R,5S,6S)-2-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazolium-6-yl)]thio-6-[R-1-hydroxyethyl]-1-methyl-carbapenum-3-carboxylate
US5061729A (en) * 1988-06-08 1991-10-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same
DE69019610D1 (de) * 1989-07-06 1995-06-29 Banyu Pharma Co Ltd Cyclische Derivate des Amidinylthiocarbapenems.
CA2022382A1 (en) * 1989-08-02 1991-02-03 Susumu Nakagawa Piperidylthiocarbapenem derivatives

Also Published As

Publication number Publication date
DE69232598T2 (de) 2002-11-21
DE69233529D1 (de) 2005-07-14
DE69233529T2 (de) 2005-11-24
EP0497353B1 (de) 2002-05-08
US5354748A (en) 1994-10-11
EP0497353A3 (en) 1992-12-02
ATE297205T1 (de) 2005-06-15
EP1161947A3 (de) 2002-07-03
US5637612A (en) 1997-06-10
DE69232598D1 (de) 2002-06-13
EP1161947A2 (de) 2001-12-12
EP0497353A2 (de) 1992-08-05
ES2244529T3 (es) 2005-12-16
ES2176179T3 (es) 2002-12-01
EP1161947B1 (de) 2005-06-08

Similar Documents

Publication Publication Date Title
HUT48116A (en) Medicaments comprising phenyl mercapto derivatives
AU6270286A (en) Therapeutic nucleosides
ATE217195T1 (de) Verwendung von cilastatin, glutathione und n- acetyl-l-cysteine zur herstellung eines arzneimittels zur verbesserung der resorption von carbapenem oder penem antibiotika im magen-darm- trakt
AU5586790A (en) Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides, processes for their preparation and their use in medicaments
EP0235589A3 (en) Use of quinolone and naphthyridine antibiotics for the manufacture of ophthalmic medicaments
AU6684894A (en) Bicyclic amide derivatives and their use as muscle relaxants
AU5237598A (en) Ethylidene derivatives of tricyclic carbapenems
CA2020346A1 (en) Antibiotic ge 2270 factors a1, a2, a3 and h
AU642259B2 (en) Novel 3,3'-dithiobis (propionic acids) and esters thereof
MY104109A (en) Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin a derivatives.
CA2037779A1 (en) Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
AU4734993A (en) Nutrient or medicinal compositions for administration to ruminants
AU5707090A (en) Hair treatment composition
NO159767C (no) Anvendelse av et hjelpestoff som tilsetning til beta-laktamantibiotikum for aa oeke absorpsjonsgraden av antibiotikumet i blodet ved oral administrering.
EP0529410A3 (en) Antibiotic ge 2270 factor c2a
AU545885B2 (en) Oral absorption of glycosidic antibiotics
GR3026590T3 (en) Antibiotics ge 37468 a, b and c.
IE782383L (en) Monic acid derivatives
GB8818789D0 (en) Crystalline(5r 6s)-2-carbamoyloxymethyl-6-((1r)-hydroxyethyl)-2-penem-carboxylic acid & pharmaceutical formulation
GR3004095T3 (de)
EP0359062A3 (de) Antibiotikum GE 2270
AU2776389A (en) Beta-lactam antibiotics, processes for their preparation and their use as and in medicaments
ES8600767A1 (es) Un procedimiento para la preparacion de derivados de 7-oxo-1-azabiciclo (3.2.0) hepteno
IT1245390B (it) Composizione farmaceutica ad attivita' antivirale

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties